Rani Therapeutics Stock Quote RANI - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

7.168

Bid

6.85

Ask

7.21

Volume

477,912

6.24 Day's Range 7.25

1.82 52 Week Range 8.75

Market Cap

355.975M

Previous Close

6.37

Open

6.39

Last Trade

7.2

Last Trade Time

Financial Volume

$ 3,311,850

VWAP

6.9298

Average Volume (3m)

136,225

Shares Outstanding

49,996,508

Dividend Yield

PE Ratio

-10.48

Earnings Per Share (EPS)

-0.68

Revenue

Net Profit

-33.97M

Rani Therapeutics Holdings Inc is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. The company has developed the RaniPill capsule, a proprietary and patented platform technology, intended to replace subcutaneous or IV injecti... Rani Therapeutics Holdings Inc is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. The company has developed the RaniPill capsule, a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.ranitherapeutics.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Rani Therapeutics Holdings Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RANI. The last closing price for Rani Therapeutics was $6.37. Over the last year, Rani Therapeutics shares have traded in a share price range of $ 1.82 to $ 8.75.

Rani Therapeutics currently has 49,996,508 shares outstanding. The market capitalization of Rani Therapeutics is $355.98 million. Rani Therapeutics has a price to earnings ratio (PE ratio) of -10.48.

Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)

- RT-111 achieved high bioavailability in humans - - RT-111 was well-tolerated, with no serious adverse events - - Celltrion has right of first negotiation to acquire worldwide rights to RT-111...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.688	10.6172839506	6.48	7.25	5.8	130464	6.42166982	CS
4	3.468	93.7297297297	3.7	8.75	3.52	246399	6.56844589	CS
12	3.368	88.6315789474	3.8	8.75	2.85	136225	5.38899746	CS
26	5.268	277.263157895	1.9	8.75	1.87	118491	4.31256244	CS
52	2.348	48.7136929461	4.82	8.75	1.82	86339	4.08113832	CS
156	-4.092	-36.3410301954	11.26	36.27	1.82	84688	11.33478692	CS
260	-4.092	-36.3410301954	11.26	36.27	1.82	84688	11.33478692	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BENFBeneficient	$ 6.8001 (254.17%)	31.01M
SGBXSafe and Green Holdings Corporation	$ 5.49 (87.37%)	92.18M
SHOTWSafety Shot Inc	$ 0.45 (45.16%)	644
AIPArteris Inc	$ 8.185 (38.03%)	1.11M
RGFReal Good Food Company Inc	$ 0.85 (37.32%)	4.26M
MNDRMobile health Network Solutions	$ 3.33 (-84.91%)	18.76M
NUVOHoldco Nuvo Group DG Ltd	$ 2.00 (-57.54%)	1.04M
SPTSprout Social Inc	$ 28.82 (-40.15%)	13.47M
UNITUniti Group Inc	$ 4.441 (-26.35%)	21.07M
IPDNProfessional Diversity Network Inc	$ 1.29 (-24.12%)	662.59k
AAPLApple Inc	$ 183.38 (5.98%)	163.22M
SQQQProShares UltraPro Short QQQ	$ 11.08 (-5.94%)	154.59M
JAGXJaguar Health Inc	$ 0.3164 (7.91%)	142.47M
NKLANikola Corporation	$ 0.6526 (6.55%)	106.88M
SGBXSafe and Green Holdings Corporation	$ 5.49 (87.37%)	92.18M